6/7
04:00 pm
mcrb
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/7
01:05 pm
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "market perform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..
Medium
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "market perform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..
6/7
09:04 am
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $15.00 to $10.00. They now have a "buy" rating on the stock.
High
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $15.00 to $10.00. They now have a "buy" rating on the stock.
6/6
07:07 am
mcrb
Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023 [Yahoo! Finance]
High
Report
Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023 [Yahoo! Finance]
6/6
07:00 am
mcrb
Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023
High
Report
Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023
6/6
06:36 am
mcrb
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science [Yahoo! Finance]
High
Report
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science [Yahoo! Finance]
6/6
06:30 am
mcrb
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science
High
Report
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science
5/31
06:27 am
mcrb
Analysis of the Global Sepsis Pipeline, 2024 with Insights on 30+ Companies and 35+ Pipeline Drugs, Including Thymosin Alpha 1 (Sci Clone Pharmaceuticals) and Enibarcimab (AdrenoMed) [Yahoo! Finance]
Low
Report
Analysis of the Global Sepsis Pipeline, 2024 with Insights on 30+ Companies and 35+ Pipeline Drugs, Including Thymosin Alpha 1 (Sci Clone Pharmaceuticals) and Enibarcimab (AdrenoMed) [Yahoo! Finance]
5/13
12:25 pm
mcrb
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/9
01:20 pm
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $5.00 to $4.00. They now have an "outperform" rating on the stock.
Medium
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $5.00 to $4.00. They now have an "outperform" rating on the stock.
5/9
09:08 am
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its price target lowered by analysts at Chardan Capital from $8.00 to $6.00. They now have a "buy" rating on the stock.
High
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its price target lowered by analysts at Chardan Capital from $8.00 to $6.00. They now have a "buy" rating on the stock.
5/9
07:29 am
mcrb
Seres Therapeutics First Quarter 2024 Earnings: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023) [Yahoo! Finance]
High
Report
Seres Therapeutics First Quarter 2024 Earnings: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023) [Yahoo! Finance]
5/8
09:55 am
mcrb
World $2.5 Bn Human Microbiome Market Trends, Forecasts and Competitive Analysis 2018-2023 and 2024-2030 [Yahoo! Finance]
Low
Report
World $2.5 Bn Human Microbiome Market Trends, Forecasts and Competitive Analysis 2018-2023 and 2024-2030 [Yahoo! Finance]
5/8
07:08 am
mcrb
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
Medium
Report
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
5/8
07:00 am
mcrb
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
High
Report
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
5/6
04:01 pm
mcrb
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/6
09:30 am
mcrb
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
Low
Report
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
4/9
07:12 am
mcrb
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT [Yahoo! Finance]
Medium
Report
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT [Yahoo! Finance]
4/9
07:00 am
mcrb
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
Medium
Report
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
4/5
05:06 am
mcrb
Global Microbiome Manufacturing Industry Research 2024: A $187 Billion Market by 2035 with Close to 170 Trials Evaluating Microbiome Therapeutics to Treat Infectious Diseases and Oncological Disorders [Yahoo! Finance]
Low
Report
Global Microbiome Manufacturing Industry Research 2024: A $187 Billion Market by 2035 with Close to 170 Trials Evaluating Microbiome Therapeutics to Treat Infectious Diseases and Oncological Disorders [Yahoo! Finance]
3/28
01:13 pm
mcrb
Increases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for now [Yahoo! Finance]
Low
Report
Increases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for now [Yahoo! Finance]
3/28
07:00 am
mcrb
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/19
07:00 am
mcrb
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)